IBA signs India's first public proton therapy centre
The future centre will be built at Guwahati Medical College, and the first patients are expected to be treated by the end of 2029. The contract, announced on 5 November 2026, covers both the installation of equipment and its multi-year operation.
A Proteus ONE and a multi-year maintenance contract in Guwahati
IBA has signed this contract with the government of the State of Assam to install the first public proton therapy centre in India. The project includes the installation of the compact Proteus ONE solution from the Belgian group, as well as a multi-year operation and maintenance contract.
The centre is being developed as part of the Assam State Secondary Healthcare Initiative for Service Delivery Transformation (ASSIST) project, which aims to transform the healthcare services offered in the state. Henri de Romrée, Deputy Chief Executive Officer of IBA, stated that the group would work with the government of Assam and AHIDMS to complete this installation.
An entry into the order book conditional on payment of the deposit
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The government of Assam has obtained funding from the World Bank for this programme and plans to allocate part of it to the proton therapy project. For reference, IBA indicates that the usual price of a Proteus ONE system, including a multi-year maintenance contract, ranges between 35 and 45 million euros.
The contract will be recorded in IBA's order book upon receipt of the deposit, which is expected before the end of 2026. The signing and the entry into the order book therefore constitute two distinct milestones of the transaction.
A first for proton therapy in the Indian public sector
The centre is presented as the first proton therapy facility in the Indian public sector. Henri de Romrée stated: “The introduction of proton therapy into the Indian public healthcare system represents an important step in making this state-of-the-art cancer treatment accessible to more patients.”
Himanta Biswa Sarma, Chief Minister of the State of Assam, specified that the project will integrate “one of the most advanced forms of radiotherapy” into the public healthcare system. “Assam will thus become the first Indian state to offer this state-of-the-art treatment in a healthcare facility under its authority,” he added.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
